Ono fourth drug major to tap into Scenic tech

Netherlands-based Scenic Biotech, a company advancing modifier therapy—a radical new approach to treating genetic disorders—has announced another collaboration with a major pharma company.

The deal with Jap Ono Pharmaceutical (TYO: 4528) is a license and research agreement allowing the Japanese drugmaker to use Scenic’s Cell-Seq platform for the discovery of novel therapeutic targets.

This collaboration marks Scenic’s fourth Cell-Seq collaboration with a major pharmaceutical company, joining ongoing multi-year agreements with the Roche (ROG: SIX) subsidiary Genentech, US pharma major Bristol Myers Squibb (NYSE: BMY) and RNA interference specialist Alnylam (Nasdaq: ALNY).